Endogenous IgG-based affinity-controlled release of TRAIL exerts superior antitumor effects

Theranostics

Volumn 8, Issue 9, 2018, Pages 2459-2476

  Yang, Hao ^a   Feng, Yanru ^a   Cai, Huawei ^a   Jia, Dianlong ^a,c   Li, Heng ^a   Tao, Ze ^a   Zhong, Yi ^b   Li, Zhao ^a   Shi, Qiuxiao ^a   Wan, Lin ^a   Li, Lin ^a   Lu, Xiaofeng ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c LIAOCHENG UNIVERSITY   (China)

Author keywords

Affinity controlled release; Albumin; Biopharmaceuticals; Drug delivery; Immunoglobulin

Indexed keywords

ALBUMIN; DEATH RECEPTOR; IMMUNOGLOBULIN G; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC AGENT; FUSION PROTEIN; PROTEIN BINDING; SERUM ALBUMIN; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; BIOCOMPATIBILITY; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PROTEIN BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VIVO STUDY; INTERFEROMETRY; MOUSE; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; SIZE EXCLUSION CHROMATOGRAPHY; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; DELAYED RELEASE FORMULATION; DRUG EFFECT; HALF LIFE TIME; HCT 116 CELL LINE; PHARMACOLOGY; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE; CELL LINE, TUMOR; DELAYED-ACTION PREPARATIONS; HALF-LIFE; HCT116 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; SERUM ALBUMIN; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 85045277548     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.23880     Document Type: Article

References (44)

1. Wash G. Biopharmaceutical benchmarks 2014. Nat Biotech. 2014;32:992-1000
2. Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov. 2014;13:655-72
3. Pakulska MM MS, Shoichet MS. Designer protein delivery: from natural to engineered affinity-controlled release systems. Science. 2016;351:aac4750
4. Vaishya R, Khurana V, Patel S, Mitra AK. Long-term delivery of protein therapeutics. Expert Opin Drug Deliv. 2015;12:415-40
5. Shah DK. Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics. J Pharmacokinet Pharmacodyn. 2015;42:553-71
6. Yun YH, Lee BK, Park K. Controlled drug delivery: historical perspective for the next generation. J Control Release. 2015;219:2-7
7. Doppalapudi S, Jain A, Domb AJ, Khan W. Biodegradable polymers for targeted delivery of anti-cancer drugs. Expert Opin Drug Deliv. 2016;13:891-909
8. Siepmann JS, et al. Swelling controlled drug delivery systems. In Fundamentals and Applications of Controlled Release Drug Delivery; Siepmann, J, Siegel, R A, Rathbone, M J, Eds; Springer: New York, 2012:153-70
9. Martinez Rivas CJ, Tarhini M, Badri W, Miladi K, Greige-Gerges H, Nazari QA, et al. Nanoprecipitation process: from encapsulation to drug delivery. Int J Pharm. 2017;532:66-81
10. Bahrami B, Hojjat-Farsangi M, Mohammadi H, Anvari E, Ghalamfarsa G, YousefiM, et al. Nanoparticles and targeted drug delivery in cancer therapy. Immun Lett. 2017;190:64-83
11. Vulic K, Shoichet MS. Affinity-based drug delivery systems for tissue repair and regeneration. Biomacromolecules 2014;15:3867-80
12. Delplace V, Obermeyer J, Shoichet MS. Local affinity release. ACS Nano. 2016;10:6433-6
13. An B, Lin YS, Brodsky B. Collagen interactions: drug design and delivery. Adv Drug Deliv Rev. 2016;97:69-84
14. Vulic K, Pakulska MM, Sonthalia R, Ramachandran A, Shoichet MS. Mathematical model accurately predicts protein release from an affinity-based delivery system. J Control Release. 2015;197:69-77
15. Stahl S, Graslund T, Eriksson Karlstrom A, Frejd FY, Nygren PA, Lofblom J. Affibody molecules in biotechnological and medical applications. Trends Biotechnol. 2017;35:691-712
16. Richter A, Eggenstein E, Skerra A. Anticalins: exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins. FEBS Lett. 2014;588:213-8
17. Lipovsek D. Adnectins: engineered target-binding protein therapeutics. Protein Eng Des Sel. 2011; 24:3-9
18. Wu X, Chen J, Wu M, Zhao JX. Aptamers: active targeting ligands for cancer diagnosis and therapy. Theranostics 2015;5:322-44
19. Park K. Enhanced antitumor effects of hTRAIL by binding to endogenous albumin. J Control Release. 2016;228:206
20. Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol. 2011;22:868-76
21. Larsen MT, Kuhlmann M, Hvam ML, Howard KA. Albumin-based drug delivery: harnessing nature to cure disease. Mol Cell Ther. 2016;4:3
22. Nilvebrant J, Hober S. The albumin-binding domain as a scaffold for protein engineering. Comput Struct Biotechnol J. 2013;6:e201303009
23. Kontermann RE. Strategy to extending half-life of recombinant antibody. BioDrugs. 2009;23:93-109
24. Hutt M, Farber-Schwarz A, Unverdorben F, Richter F, Kontermann RE. Plasma half-life extension of small recombinant antibodies by fusion to immunoglobulin-binding domains. J Biol Chem. 2012; 287: 4462-9
25. Sockolosky J, Kivimäe S, Szoka FC. Fusion of a short peptide that binds immunoglobulin G to a recombinant protein substantially increases its plasma half-life in mice. PloS One. 2014;9:e102566
26. Mouratou B, Behar G, Pecorari F. Artificial affinity proteins as ligands of immunoglobulins. Biomolecules. 2015;5:60-75
27. Kruljec N, Bratkovic T. Alternative affinity ligands for immunoglobulins. Bioconjug Chem. 2017; 28:2009-30
28. Micheau O, Shirley S, Dufour F. Death receptors as targets in cancer. Br J Pharmacol. 2013;169:1723-4
29. Muller N, Schneider B, Pfizenmaier K, Wajant H. Superior serum half life of albumin tagged TNF ligands. Biochem Biophys Res Commun. 2010;396:793-9
30. Wang H, Davis JS, Wu X. Immunoglobulin Fc domain fusion to TRAIL significantly prolongs its plasma half-life and enhances its antitumor activity. Mol Cancer Ther. 2014;13:643-50
31. Chae SY, Kim TH, Park K, Jin CH, Son S, Lee S, et al. Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand. Mol Cancer Ther. 2010;9:1719-29
32. De Miguel D, Gallego-Lleyda A, Ayuso JM, Erviti-Ardanaz S, Pazo-Cid R, del Agua C, et al. TRAIL-coated lipid-nanoparticles overcome resistance to soluble recombinant TRAIL in non-small cell lung cancer cells. Nanotechnology. 2016;27:185101
33. Nair PM, Flores H, Gogineni A, Marsters S, Lawrence DA, Kelley RF, et al. Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display. Proc Natl Acad Sci U S A, 2015;112:5679-84
34. Li R, Yang H, Jia D, Nie Q, Cai H, Fan Q, et al. Fusion to an albumin-binding domain with a high affinity for albumin extends the circulatory half-life and enhances the in vivo antitumor effects of human TRAIL. J Control Release. 2016;228:96-106
35. Unverdorben F, Hutt M, Seifert O, Kontermann RE. A Fab-selective immunoglobulin-binding domain from streptococcal protein G with improved half-life extension properties. PloS One. 2015;10: e0139838
36. Jia D, Yang H, Tao Z, Wan L, Cheng J, Lu X. Preparation and characterization of a novel variant of human tumor necrosis factor-related apoptosis-inducing ligand from the rhesus monkey, Macaca mulatta. Appl Micro Biotech. 2016;100:3035-47
37. Hofstrom C, Orlova A, Altai M, Wangsell F, Graslund T, Tolmachev V. Use of a HEHEHE purification tag instead of a hexahistidine tag improves biodistribution of affibody molecules site-specifically labeled with (99m)Tc, (111)In, and (125)I. J Med Chem. 2011;54:3817-26
38. Stork R, Muller D, Kontermann RE. A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G. Protein Eng Des Sel. 2007;20:569-76
39. Goebl NA, Babbey CM, Datta-Mannan A, Witcher DR, Wroblewski VJ, Dunn KW. Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells. Mol Biol Cell. 2008;19:5490-505
40. Fan Q, Cai H, Yang H, Li L, Yuan C, Lu X, et al. Biological evaluation of 131Iand CF750-labeled Dmab(scFv)-Fc antibodies for xenograft imaging of CD25-positive tumors. BioMed Res Int. 2014;2014:459676
41. Wang F, Chen L, Zhang R, Chen Z, Zhu L. RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer. J Control Release. 2014; 196:222-33
42. Rath T, Baker K, Dumont JA, Peters RT, Jiang H, Qiao SW, et al. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol. 2015; 35:235-54
43. Pyzik M, Rath T, Lencer WI, Baker K, Blumberg RS. FcRn: The architect behind the immune and nonimmune functions of IgG and albumin. J Immunol. 2015;194:4595-603
44. Unverdorben F, Richter F, Hutt M, Seifert O, Malinge P, Fischer N, et al. Pharmacokinetic properties of IgG and various Fc fusion proteins in mice. MAbs. 2016;8:120-8